VRDN
HealthcareViridian Therapeutics, Inc.
$30.20
$-0.48 (-1.56%)
Jan 5, 2026
Price History (1Y)
Analysis
Viridian Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $2.88 billion and annual revenue of $70.79 million, the company maintains a significant presence in its industry. Its workforce comprises 143 employees. Financially, Viridian Therapeutics has reported a net loss of approximately $245.32 million over the trailing twelve months. The company's operating margin stands at -56.7%, while its gross and profit margins are both at 0.0%. From an asset utilization perspective, returns on equity and assets are -49.9% and -30.1%, respectively. Notably, Viridian Therapeutics has a substantial amount of cash reserves at $490.90 million, albeit with a relatively low debt level of $24.20 million. In terms of valuation context, Viridian Therapeutics' forward P/E ratio is -8.52, indicating significant variation from its historical earnings performance. The company's revenue growth rate over the past year has been substantial, at 81958.1%. Dividend information is not available for the company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $2.88B
- P/E Ratio
- N/A
- 52-Week High
- $34.04
- 52-Week Low
- $9.90
- Avg Volume
- 1.63M
- Beta
- 0.94
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 143